2. Academic Validation
  3. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

  • Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. doi: 10.1016/j.bmcl.2012.05.098.
Les A Dakin 1,  Michael H Block,  Huawei Chen,  Erin Code,  James E Dowling,  Xiaomei Feng,  Andrew D Ferguson,  Isabelle Green,  Alexander W Hird,  Tina Howard,  Erika K Keeton,  Michelle L Lamb,  Paul D Lyne,  Hannah Pollard,  Jon Read,  Allan J Wu,  Tao Zhang,  Xiaolan Zheng
Affiliations

Affiliation

  • 1 Oncology iMed Sciences Group, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
PMID: 22727640 DOI: 10.1016/j.bmcl.2012.05.098
Abstract

Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the Pim kinases. The synthesis and SAR of these compounds are described, along with X-ray crystallographic, anti-proliferative, and selectivity data.

Figures
Products